XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-09-28
Target enrollment:
Participant gender:
Summary
The trial is divided into two parts, one is dose escalation phase, the second one is dose
expansion phase.
For dose escalation phase, the main purpose is to evaluate safety and tolerability of
XZP-5809-TT1 tablets after treatment with epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) in patients With T790M Mutation-positive Locally Advanced or Metastatic
Non-small Cell Lung Cancer, and to determine the maximum tolerated dose (MTD) and
dose-limiting toxicity (DLT).
For dose expansion phase, the main purpose is to evaluate Objective response rate (ORR) in
patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung
Cancer.